

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/003602-2022>

Tender

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema

The NHS Commissioning Board (operating under the name of NHS England)

F02: Contract notice

Notice identifier: 2022/S 000-003602

Procurement identifier (OCID): ocds-h6vhtk-0314ad

Published 8 February 2022, 3:38pm

Section I: Contracting authority

I.1) Name and addresses

The NHS Commissioning Board (operating under the name of NHS England)

2nd Floor, Rutland House

Runcorn

WA7 2ES

Contact

Philip Grieve

Email

philip.grieve@nhs.net

Country

United Kingdom

NUTS code

UK - United Kingdom

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<http://health.atamis.co.uk>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<http://health.atamis.co.uk>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<http://health.atamis.co.uk>

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema

Reference number

CM/PHS/19/5583

II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

II.1.3) Type of contract

Supplies

II.1.4) Short description

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.1.5) Estimated total value

Value excluding VAT: £198,666,666

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

II.2.1) Title

Lot 1 – C1 Esterase – Recombinant IV (acute treatment)

Lot No

Lot 1

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33141520 - Plasma extracts
- 33141510 - Blood products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

II.2.4) Description of the procurement

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2022

End date

31 December 2023

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)

Lot No

Lot 3

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33141520 - Plasma extracts
- 33141510 - Blood products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

II.2.4) Description of the procurement

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2022

End date

31 December 2023

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 6 - Lanadelumab

Lot No

Lot 6

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33141520 - Plasma extracts
- 33141510 - Blood products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

II.2.4) Description of the procurement

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2022

End date

31 December 2023

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 7 - Berotralstat

Lot No

Lot 7

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33141510 - Blood products
- 33141520 - Plasma extracts

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

II.2.4) Description of the procurement

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2022

End date

31 December 2023

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)

Lot No

Lot 2

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33141520 - Plasma extracts
- 33141510 - Blood products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

II.2.4) Description of the procurement

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2022

End date

31 December 2023

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)

Lot No

Lot 4

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33141520 - Plasma extracts
- 33141510 - Blood products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

II.2.4) Description of the procurement

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2022

End date

31 December 2023

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 5 - Icatibant

Lot No

Lot 5

II.2.2) Additional CPV code(s)

- 33600000 - Pharmaceutical products
- 33141520 - Plasma extracts
- 33141510 - Blood products

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Wales, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

II.2.4) Description of the procurement

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 July 2022

End date

31 December 2023

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III. Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

16 March 2022

Local time

1:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 14 June 2022

IV.2.7) Conditions for opening of tenders

Date

16 March 2022

Local time

1:00pm

Place

Runcorn

Information about authorised persons and opening procedure

Commercial Medicines Unit Employee

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3) Additional information

RESPONDING TO THIS NOTICE:

Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information

This procurement exercise will be conducted on the eTendering portal at

<https://healthfamily.force.com/s/Welcome>

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:

1.1) If not already registered, Candidates should register on the eTendering portal at

<https://health-family.force.com/s/Welcome> and click the link to register:

- agree to the user agreement
- populate company details

1.2) Once registered, candidates must register interest as follows:

- log to the portal
- select "Find Opportunities" from the supplier home screen, use the "Sort by:" facility to find this opportunity and select the bold blue title to select review opportunity details and click "Register Interest"
- as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity)

1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis help desk at supporthealth@atamis.co.uk or by calling 0800 9956035 for technical assistance when completing responses.

2) General supplier information.

To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:

2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page

<https://supplierregistration.cabinetoffice.gov.uk> and select "Register" at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B.

Candidates must obtain a Dun & Bradstreet(D&B) D-U-N-S® Number to enable registration on the system.

2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.

D&B data will be supplied automatically by D&B.

2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the message function on the website.

OTHER CONTRACTING AUTHORITIES

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

VI.4) Procedures for review

VI.4.1) Review body

The High Court

Strand

London

WC2A 2LL

Email

generaloffice@administrativecourtoffice.justice.gov.uk

Country

United Kingdom

Internet address

<https://www.gov.uk/courts-tribunals>